Palatin Technologies Announces Option for License to Bremelanotide

TN) Option for License to Bremelanotide in Europe" rel="nofollow" href="http://crwepressrelease.com/4383/news-by-category/health-medical/palatin-technologies-announces-option-for-license-to-bremelanotide-in-europe/" target="_blank">

CRANBURY, NJ – November 13, 2013 – (CRWE Press Release) - Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.

Palatin received a $1.0 million, non-refundable option fee under the option agreement. Subject to certain contingencies, if not exercised the option expires in the first calendar quarter of 2014.

The option agreement is with a European specialty pharmaceutical company with pharmaceutical manufacturing, research and development, and sales and marketing capabilities. As part of the option agreement, the parties are seeking regulatory advice from the European Medicines Agency on phase 3 clinical data required for approval of bremelanotide for female sexual dysfunction in the European Union.

“We believe that the two largest potential markets for bremelanotide are the United States and the European Union,” stated Carl Spana, Ph.D., President and CEO of Palatin. “Based on a number of factors, it may be most effective to have separate partners for the United States and for the European Union. We are pleased with the relationship with our potential European partner, which has extensive European regulatory experience and has been instrumental in preparing for our meeting with the European Medicines Agency. We are optimistic we will be able to successfully conclude a definitive agreement with them on European commercialization of bremelanotide for female sexual dysfunction. We are also in active discussions with multiple pharmaceutical companies on commercialization of bremelanotide in the United States, and hope to be able to select a potential partner this year and proceed to negotiation of definitive agreements early next year.”

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at http://www.palatin.com .

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about the prospects of entering into one or more license agreements relating to bremelanotide, potential clinical trial results with bremelanotide, potential actions by regulatory agencies in the United States or Europe relating to bremelanotide, regulatory plans, development programs and the market potential of bremelanotide are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, the ability of Palatin to enter into one or more agreements relating to the commercialization of bremelanotide, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and other regulatory agencies and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

Contact

Palatin Technologies Investor Inquiries:
Stephen T. Wills, CPA, MST
Chief Operating Officer / Chief Financial Officer
Tel: (609) 495-2200 / info@palatin.com

Palatin Technologies Media Inquiries:
Paul Arndt, MBA, LifeSci Advisors, LLC
Managing Director
Tel: (646) 597-6992 / aul@LifeSciAdvisors.com"> Paul@LifeSciAdvisors.com

Source: Palatin Technologies, Inc.